Key result
Cosyntropin infusion significantly attenuated baroreflex sensitivity compared to placebo during the infusion (14.4 vs 17.3 mm Hg/ms) and the next day (14.8 vs 18.9 mm Hg/ms; P<.05).
Why the study?
Hypoglycemia attenuates baroreflex sensitivity in cardiovascular hypoglycemia-associated autonomic failure, but the underlying role of the adrenocorticotropin-adrenal axis remains unclear.
Does intravenous cosyntropin infusion reduce baroreflex sensitivity in healthy men and women?
RCT
Double-blind
random-order
No
Does intravenous cosyntropin infusion reduce baroreflex sensitivity in healthy men and women?
Absolute Event Rate: 14.4% vs 17.3%
p-value: p=<.05
ACTH infusion acutely and persistently attenuates baroreflex sensitivity, suggesting a mechanism for the cardiovascular component of hypoglycemia-associated autonomic failure.
No takes yet. Share an insight, caveat, or question.
Hypoglycemia-induced BRS reduction warrants vigilant glycemic control in CV patients; extends mechanistic understanding of HAAF.
Leung et al. (2020) conducted an RCT in Healthy. Cosyntropin (ACTH 1-24) vs. Normal saline placebo was evaluated on Baroreflex sensitivity (BRS) during and 16 hours after cosyntropin vs placebo infusions (p=<.05). Cosyntropin infusion significantly attenuated baroreflex sensitivity compared to placebo during the infusion (14.4 vs 17.3 mm Hg/ms) and the next day (14.8 vs 18.9 mm Hg/ms; P<.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: